drugset / Trial / NCT05233657

A Safety,Tolerability and Pharmacokinetics Clinical Trial of JX11502MA Capsule

NCT05233657 ↗

Phase 1 Unknown 58 enrolled Zhejiang Jingxin Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the safety, tolerability and pharmacokinetic characteristics of JX11502MA capsule on healthy human, and to explore the relationship between the dose, pharmacokinetic parameters and safety of JX11502MA capsule,so as to provide basis for the follow-up clinical trials (multi-dose tolerability, pharmacokinetics and phase II trial, etc.).

Timeline

Start
2020-01-04
Primary completion
2022-01-31
Completion
2022-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject JX11502MA Unknown 0.25 mg Oral
Subject JX11502MA Unknown 0.5 mg Oral
Subject JX11502MA Unknown 1 mg Oral
Subject JX11502MA Unknown 2 mg Oral
Subject JX11502MA Unknown 3 mg Oral
Subject JX11502MA Unknown 6 mg Oral
Subject JX11502MA Unknown 8 mg Oral

Indications